#ACR21 Ab#L02 - #COVID19 vax in rheumatic pts: ❌No ⬆️ in disease activity scores post-vaccination ❌No serious adverse event ▶️Vax response 88% in RA, 78% in SLE, 87% other rheum diseases after 2 shots vs 100% controls ⭐️RTX and MMF ⬇️ responses @Rheumnow https://t.co/BChhmW0jpy https://t.co/2q8IKRoYqW

• https://bit.ly/3kkT94g

Dr Coras on "ITIS" anti-inflammatory diet in RA. Improves fatigue after 2 weeks. Fatigue response dissociated from disease activity response. Open label, but promising. Fatigue remains one of our biggest challenges in RA. Abstr#1699 #ACR21 @RheumNow @ElenaNikiUK https://t.co/tBMqmWAy8m

#Depression is associated with a 3x increased mortality risk in patients with incident #RA. 👉🏼Results from #DANBIO 👉🏼~11000 RA pts, ~1000 starting antidepressants Abs#1659 #ACR21 @RheumNow https://t.co/SsEjmLzacP https://t.co/1GiFE0KLjK

• Increased All-Cause Mortality Risk in Patients with Incident Rheumatoid Arthrit…

#ACR21 L10 TRAIL1: Pirfenidone for RA-ILD ⭐️Low pt enrollment due to pandemic, 1/2 of planned trial size ▶️ Unable to meet primary endpt (composite death+FVC) but met FVC markers. Most pronounced in UIP patterns on HRCT @Rheumnow https://t.co/HB7N9Wl9Dn https://t.co/muBEguAAja

• https://bit.ly/3qkIsm1

#Sleep disturbance is common in #RA but does it correlate with disease activity? Results from >100 RA pts suggest yes. Many reported sleep disturbances, associated with both incr patient & physician-assessed disease activity. Abs#1666 #ACR21 @RheumNow https://t.co/ud2uMf25cI https://t.co/BE4UHPB0f1

• Association of Objectively Measured Sleep Characteristics with Rheumatoid Arthr…

Predicting RA, and Treatment of Subclinical Arthritis Dr. Meral K. El Ramahi ( @MeralElRamahiMD) shares the abstracts discussed at #ACR21 focusing on predicting RA and treating subclinical arthritis. https://t.co/DYgV43JpgT https://t.co/U2NfXrfYZU

• https://bit.ly/3BVc9wa

My article on the potential use of BMI to guide biologic selection in RA. Discussing #ACR21 abstract 0588 by @MilenaGianfran @JYazdanyMD https://t.co/hxliSZ3IBS @RheumNow

• The Influence of Obesity on Choice of Biologic Agent in Rheumatoid Arthritis | …

Watch my video discussion of #ACR21 abstract 564 from @KronzerMD @jeffsparks on the association of upper airways disease with incident RA. https://t.co/Nkg9Yl9yYT @RheumNow

Avoid IFX drug holidays! In this study 400+ pts Dvlpmt of ADAs associated w/ ▶️RA vs. SPA OR 2.1 ▶️Smoking OR 1.8 ▶️Drug holidays > 11 weeks OR 4.1 ▶️High DA OR 1.5 while ◀️Concomitant IS drug OR 0.4 ◀️ IFX dose increments OR 0.4, were protective #ACR21 @RheumNow #Abst1525 https://t.co/cxx7aWX5wh

Safety profile of #upadacitinib in #RA, #PsA, #AnkylosingSpondylitis 👉🏼AE rates similar across UPA, ADA & MTX in RA, and UPA & ADA in PsA 👉🏼No new safety risks with long-term use 👉🏼#Herpeszoster & incr CPK more common w/ UPA vs ADA/MTX Abs#1691 #ACR21 @RheumNow https://t.co/tKYi65kB5r

SELECT-EARLY results for #upadacitinib in #RA 👉🏼UPA better than MTX for clinical response and remission 👉🏼⬆️rates of HZ, neutropenia, CPK elevations 👉🏼No new safety risks identified Abs#1692 #ACR21 @RheumNow https://t.co/wJy7MK4pyF https://t.co/YNpE1Axiw0

• Long-Term Efficacy and Safety of Upadacitinib in Patients with Rheumatoid Arthr…

The Influence of Obesity on Choice of Biologic Agent in Rheumatoid Arthritis Dr. Richard Conway ( @RichardPAConway) reviews an abstract presented at #ACR21. https://t.co/PkJmpODz8v https://t.co/zuJjofka3B

• https://bit.ly/31v9wVd